Current opinion of aromatase inhibitor-induced arthralgia in breast cancer in the UK

Clinical Oncology

Volumn 23, Issue 10, 2011, Pages 674-680

  Din, O S ^a   Dodwell, D ^b   Winter, M C ^a   Mori, S ^a   Coleman, R E ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Aromatase; Arthralgia; Breast; Cancer; Inhibitor

Indexed keywords

ANTIINFLAMMATORY AGENT; AROMATASE INHIBITOR; EXEMESTANE; NARCOTIC ANALGESIC AGENT; TAMOXIFEN;

ARTHRALGIA; ARTICLE; BREAST CANCER; HUMAN; PRIORITY JOURNAL; QUESTIONNAIRE; SURGEON; UNITED KINGDOM;

AROMATASE INHIBITORS; ARTHRALGIA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GREAT BRITAIN; HUMANS; PRACTICE GUIDELINES AS TOPIC; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80055118498     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2011.06.007     Document Type: Article

References (32)

1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365(9472):1687-1717. EBCTCG.
2. Bonneterre J., Thurlimann B., Robertson J.F., et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol 2000, 18(22):3748-3757.
3. Mouridsen H., Gershanovich M., Sun Y., et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the international letrozole breast cancer group. J Clin Oncol 2003, 21(11):2101-2109.
4. Nabholtz J.M., Buzdar A., Pollak M., et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex study group. J Clin Oncol 2000, 18(22):3758-3767.
5. Howell A., Cuzick J., Baum M., et al. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365(9453):60-62.
6. Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003, 349(19):1793-1802.
7. Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004, 350(11):1081-1092.
8. Coombes R.C., Kilburn L.S., Snowdon C.F., et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (intergroup exemestane study): a randomised controlled trial. Lancet 2007, 369(9561):559-570.
9. Jakesz R., Jonat W., Gnant M., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005, 366(9484):455-462.
10. Thurlimann B., Keshaviah A., Coates A.S., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005, 353(26):2747-2757.
11. Boccardo F., Rubagotti A., Guglielmini P., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 2006, 17(Suppl. 7):vii10-vii14.
12. Crew K.D., Greenlee H., Capodice J., et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007, 25(25):3877-3883.
13. Presant C.A., Bosserman L., Young T., et al. Aromatase inhibitor-associated arthralgia and/or bone pain: frequency and characterization in non-clinical trial patients. Clin Breast Cancer 2007, 7(10):775-778.
14. Dent SF, Hopkins S, Di Valentin T, et al. Adjuvant aromatse inhibitors in early breast cancer - toxicity and adherence. Important observations in clinical practice. San Antonio Breast Cancer Symposium, 2007. San Antonio, Texas.
15. Henry N.L., Giles J.T., Ang D., et al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 2008, 111(2):365-372.
16. Sestak I., Cuzick J., Sapunar F., et al. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol 2008, 9(9):866-872.
17. Thorne C. Management of arthralgias associated with aromatase inhibitor therapy. Curr Oncol 2007, 14(Suppl. 1):S11-19.
18. Coleman R.E., Bolten W.W., Lansdown M., et al. Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev 2008, 34(3):275-282.
19. Crew K.D., Capodice J., Greenlee H., et al. Randomized, blinded, placebo-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. J Clin Oncol 2009, 27(15s):571.
20. Mao J.J., Bruner D.W., Stricker C., et al. Feasibility trial of electroacupuncture for aromatase inhibitor-related arthralgia in breast cancer survivors. Integr Cancer Ther 2009, 8(2):123-129.
21. Khan Q.J., Reddy P.S., Kimler B.F., et al. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 2010, 119(1):111-118.
22. Tipples K., Robinson A. Optimising care of elderly breast cancer patients: a challenging priority. Clin Oncol (R Coll Radiol) 2009, 21(2):118-130.
23. Morales L., Pans S., Paridaens R., et al. Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Res Treat 2007, 104(1):87-91.
24. Morales L., Pans S., Verschueren K., et al. Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol 2008, 26(19):3147-3152.
25. Dawson-Basoa M., Gintzler A.R. Involvement of spinal cord delta opiate receptors in the antinociception of gestation and its hormonal simulation. Brain Res 1997, 757(1):37-42.
26. Dizdar O., Ozcakar L., Malas F.U., et al. Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgia. J Clin Oncol 2009, 27(30):4955-4960.
27. Sestak I., Sapunar F., Cuzick J. Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial. J Clin Oncol 2009, 27(30):4961-4965.
28. Toesca A., Pagnotta A., Zumbo A., et al. Estrogen and progesterone receptors in carpal tunnel syndrome. Cell Biol Int 2008, 32(1):75-79.
29. Renshaw L, McHugh M, Williams L, et al. Comparison of joint problems as reported by patients in a randomised adjuvant trial of anastrozole and letrozole. San Antonio Breast Cancer Symposium, 2007:2072.
30. Briot K., Tubiana-Hulin M., Bastit L., et al. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Res Treat 2010, 120(1):127-134.
31. Cuzick J., Sestak I., Cella D., et al. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 2008, 9(12):1143-1148.
32. Din O.S., Dodwell R.J., Wakefield, et al. Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more?. Breast Cancer Res Treat 2010, 120(3):525-538.